layoffs
Black Diamond Therapeutics Restructures Workforce, Deprioritizes RAF Program
The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.
Bluebird Bio to Lay off 25 Percent of Workforce Amid Restructuring Effort
The company said it expects this restructuring plan to result in its quarterly cash flow breaking even by the second half of next year.
Achilles Therapeutics Shuts Down Engineered Cell Therapy Program, Explores Cost-Cutting Measures
The firm is discontinuing its CHIRON and THETIS trials after lackluster data and is planning for potential third-party deals and workforce layoffs.
Octernal Stopping Clinical Testing, Reducing Workforce After Safety, Efficacy Issues in Two Trials
The company said it will lay off approximately 37 percent of its workforce and stop all clinical development as it explores strategic alternatives.
IN8bio to Lay off Nearly Half of Workforce, Narrow Pipeline Focus on AML Cell Therapy
The firm is dropping two glioblastoma programs and cutting 49 percent of its staff to advance its gamma delta T-cell therapy INB-100 in post-transplant AML.
Apr 25, 2024